Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAIRS: Autologous Cord Blood-MNCs in Very Preterm Infants
NCT05087498Phase 1Completed
- Sponsor
- Guangdong Women and Children Hospital
- Start
- Nov 2021
- Primary completion
- Aug 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of autologous cord blood mononuclear cells in preterm birth (2 arms), sponsored by Guangdong Women and Children Hospital. Primary endpoints: Immunomodulation effect at 7 days, Success rate of cord blood collection at 6 months and 1 more. Started Nov 2021; status: completed.
02
Drugs
autologous cord blood mononuclear cells
03
Conditions
preterm birth
Beyond the preview
Go deeper on NCT05087498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05087498.